Antibody-Drug Conjugates SO-N106

SOTIO is developing SO-N106 as an ADC against an undisclosed target. 

SO-N106 has demonstrated potent anti-tumor efficacy in vitro and in vivo and, due to NBE’s proprietary site-specific sortase mediated antibody coupling (SMAC) conjugation platform, has superior manufacturing properties including stability and aggregation propensity.